Fundraising Fox

Engrail Therapeutics

9 known investors

engrail.com ↗

Engrail is developing therapies described as transformational. The page provides no further usable detail about the company's products, market, or industry.

Biotech

Investors · 9

F-Prime Capital PartnersCambridge · $3M – $10M
Foresite CapitalLarkspur
Longwood FundBoston
Red Tree VentureSan Diego
RiverVest Venture PartnersSt. Louis · $500K – $3M
Ysios CapitalBarcelona · $5.4M – $21.6M
F-Prime Capitalreported
ForbionreportedNaarden
Norwest Venture PartnersreportedMenlo Park · $10M – $30M

In the news

Longwood Fund - Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapieslongwoodfund.com · Mar 2024Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapiesbusinesswire.com · Mar 2024Engrail Therapeutics raises $157M Series B | Eight Roadseightroads.com · Mar 2024Mid-stage neuroscience startup Engrail raises $157Mendpoints.news · Mar 2024Engrail Raises $157M in Oversubscribed Series B to Move Neuro Pipeline Forward - BioSpacebiospace.com · Mar 2024Engrail raises $157 million in funding for anxiety meds sans the side effects | Company Business Newslivemint.com · Mar 2024

Frequently asked questions

What does Engrail Therapeutics do?
Engrail is developing therapies described as transformational. The page provides no further usable detail about the company's products, market, or industry.
Who are Engrail Therapeutics's investors?
Engrail Therapeutics's investors include F-Prime Capital Partners, Foresite Capital, Longwood Fund, Red Tree Venture, RiverVest Venture Partners, Ysios Capital, F-Prime Capital, Forbion and 1 more.